Kintara Therapeutics Inc. (KTRA) Financial Statements (2024 and earlier)

Company Profile

Business Address 9920 PACIFIC HEIGHTS BLVD, SUITE 150
SAN DIEGO, CA 92121
State of Incorp. NV
Fiscal Year End June 30
Industry (SIC) 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) (USD)

3/31/2024
MRQ
12/31/2023
MRQ
6/30/2023
6/30/2022
6/30/2021
6/30/2020
6/30/2019
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments658,0001,535,00011,780,00010,537,0002,392,4023,718,758
Cash and cash equivalents658,0001,535,00011,780,00010,537,0002,392,4023,718,758
Prepaid expense311,000660,0001,478,000756,000355,580280,248
Deferred costs     93,701 
Other undisclosed current assets217,0001,075,000 500,0009,40126,187
Total current assets:1,186,0003,270,00013,258,00011,793,0002,851,0844,025,193
Noncurrent Assets
Property, plant and equipment699,000709,00090,000150,000  
Intangible assets, net (including goodwill)     2,10912,062
Intangible assets, net (excluding goodwill)     2,10912,062
Deferred costs     84,944 
Other undisclosed noncurrent assets   2,600,0001,600,000  
Total noncurrent assets:699,000709,0002,690,0001,750,00087,05312,062
TOTAL ASSETS:1,885,0003,979,00015,948,00013,543,0002,938,1374,037,255
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities, including:1,722,0002,784,0003,269,0002,219,0002,011,0581,744,517
Other undisclosed accounts payable and accrued liabilities1,722,0002,784,0003,269,0002,219,0002,011,0581,744,517
Due to related parties298,000721,000561,000663,865325,208
Other undisclosed current liabilities148,000     
Total current liabilities:1,870,0003,082,0003,990,0002,780,0002,674,9232,069,725
Noncurrent Liabilities
Other undisclosed noncurrent liabilities179,000166,000163,000182,000  
Total noncurrent liabilities:179,000166,000163,000182,000  
Total liabilities:2,049,0003,248,0004,153,0002,962,0002,674,9232,069,725
Equity
Equity, attributable to parent, including:(164,000)731,00011,795,00010,581,000263,2141,967,530
Common stock10,0002,00066,00033,00011,4583,839
Additional paid in capital145,090,000141,438,000135,510,000106,821,00056,624,04850,954,741
Accumulated other comprehensive income21,00021,00021,00021,00021,17821,178
Accumulated deficit(155,537,000)(151,375,000)(136,356,000)(111,225,000)(69,721,233)(60,578,345)
Warrants and rights outstanding     8,524,3366,588,283
Stockholders' equity note, subscriptions receivable (103,000)     
Other undisclosed equity, attributable to parent10,355,00010,645,00012,554,00014,931,0004,803,4274,977,834
Total equity:(164,000)731,00011,795,00010,581,000263,2141,967,530
TOTAL LIABILITIES AND EQUITY:1,885,0003,979,00015,948,00013,543,0002,938,1374,037,255

Income Statement (P&L) (USD)

3/31/2024
TTM
12/31/2023
TTM
6/30/2023
6/30/2022
6/30/2021
6/30/2020
6/30/2019
Operating expenses(10,632,000)(14,796,000)(22,682,000)38,166,000(9,198,241)8,398,496
Other operating income (expense), net2,000 14,000(26,000)75,248 
Operating income (loss):(10,630,000)(14,796,000)(22,668,000)38,140,000(9,122,993)8,398,496
Nonoperating income (expense)46,000147,00021,000(132,000)72,325(350,275)
Investment income, nonoperating      (433,503)
Gain (loss), foreign currency transaction, before tax(9,000)10,0007,000(12,000)(2,923)17,746
Interest and debt expense    (30,000)  
Income (loss) from continuing operations:(10,584,000)(14,649,000)(22,647,000)37,978,000(9,050,668)8,048,221
Income (loss) before gain (loss) on sale of properties:(22,647,000)37,978,000(9,050,668)8,048,221
Other undisclosed net loss   (14,000)(76,276,000)(75,248)(16,096,442)
Net loss:(10,584,000)(14,649,000)(22,661,000)(38,298,000)(9,125,916)(8,048,221)
Other undisclosed net income attributable to parent      16,096,442
Net income (loss) attributable to parent:(10,584,000)(14,649,000)(22,661,000)(38,298,000)(9,125,916)8,048,221
Preferred stock dividends and other adjustments    (17,000)(8,616)80,431
Other undisclosed net loss available to common stockholders, basic(181,000)(370,000)(2,470,000)(3,189,000)  
Net income (loss) available to common stockholders, diluted:(10,765,000)(15,019,000)(25,131,000)(41,504,000)(9,134,532)8,128,652

Comprehensive Income (USD)

3/31/2024
TTM
12/31/2023
TTM
6/30/2023
6/30/2022
6/30/2021
6/30/2020
6/30/2019
Net loss:(10,584,000)(14,649,000)(22,661,000)(38,298,000)(9,125,916)(8,048,221)
Comprehensive loss, net of tax, attributable to parent:(10,584,000)(14,649,000)(22,661,000)(38,298,000)(9,125,916)(8,048,221)

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: